Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,563 recalls, newest first

Class II · Moderate risk

Magnesia Phosphorica 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0499-2020
Class II · Moderate risk

Kali Sulphuricum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0498-2020
Class II · Moderate risk

Kali Phosphoricum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0497-2020
Class II · Moderate risk

Kali Muriaticum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0496-2020
Class II · Moderate risk

Ferrum Phosphoricum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0495-2020
Class II · Moderate risk

Cell Salts Combination 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0494-2020
Class II · Moderate risk

Calcarea Sulphurica 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0493-2020
Class II · Moderate risk

Calcarea Phosphorica 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0492-2020
Class II · Moderate risk

Calcarea Fluorica 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0491-2020
Class II · Moderate risk

Ranitidine Syrup

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity American Health Packaging NDC 60687-260-69 D-0631-2020
Class II · Moderate risk

Potassium Phosphate

Failed Stability Specifications: Product exceeds compendia and firm's specifications for iron content.

Terminated Stability / shelf life Avantor Performance Materials Inc NDC 10106-3248-1 D-0575-2020

Recalls by year